These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27769070)

  • 1. Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.
    Fielitz K; Althoff K; De Preter K; Nonnekens J; Ohli J; Elges S; Hartmann W; Klöppel G; Knösel T; Schulte M; Klein-Hitpass L; Beisser D; Reis H; Eyking A; Cario E; Schulte JH; Schramm A; Schüller U
    Oncotarget; 2016 Nov; 7(46):74415-74426. PubMed ID: 27769070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN-mediated murine cancer models.
    Althoff K; Schramm A
    Aging (Albany NY); 2017 Apr; 9(4):1084-1085. PubMed ID: 28377536
    [No Abstract]   [Full Text] [Related]  

  • 3. Progranulin Stimulates Proliferation of Mouse Pancreatic Islet Cells and Is Overexpressed in the Endocrine Pancreatic Tissue of an MEN1 Mouse Model.
    Barbu A; Lejonklou MH; Skogseid B
    Pancreas; 2016 Apr; 45(4):533-40. PubMed ID: 26495792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple glucagon-producing pancreatic neuroendocrine tumors in a horse (Equus caballus).
    Herbach N; Nagel L; Zwick T; Hermanns W
    Vet Pathol; 2014 May; 51(3):607-11. PubMed ID: 23774746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
    Althoff K; Beckers A; Bell E; Nortmeyer M; Thor T; Sprüssel A; Lindner S; De Preter K; Florin A; Heukamp LC; Klein-Hitpass L; Astrahantseff K; Kumps C; Speleman F; Eggert A; Westermann F; Schramm A; Schulte JH
    Oncogene; 2015 Jun; 34(26):3357-68. PubMed ID: 25174395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides.
    Rindi G; Efrat S; Ghatei MA; Bloom SR; Solcia E; Polak JM
    Virchows Arch A Pathol Anat Histopathol; 1991; 419(2):115-29. PubMed ID: 1678563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.
    Takano Y; Kasai K; Takagishi Y; Kikumori T; Imai T; Murata Y; Hayashi Y
    PLoS One; 2015; 10(7):e0133812. PubMed ID: 26192435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development.
    Lu J; Herrera PL; Carreira C; Bonnavion R; Seigne C; Calender A; Bertolino P; Zhang CX
    Gastroenterology; 2010 May; 138(5):1954-65. PubMed ID: 20138042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of neuroendocrine tumors in transgenic mice.
    Rindi G
    Digestion; 1994; 55 Suppl 3():24-30. PubMed ID: 7698534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN Transforms Prostate Epithelium to Neuroendocrine Prostate Cancer.
    Cancer Discov; 2016 Jun; 6(6):OF19. PubMed ID: 27080339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN induces neuroblastoma in primary neural crest cells.
    Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
    Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
    Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
    Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
    [No Abstract]   [Full Text] [Related]  

  • 13. Serine protease inhibitor 8 is a novel immunohistochemical marker for neuroendocrine tumors of the pancreas.
    de Koning PJ; Bovenschen N; Broekhuizen R; Lips CJ; Kummer JA
    Pancreas; 2009 May; 38(4):461-7. PubMed ID: 19188865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
    Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
    Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish.
    Yang HW; Kutok JL; Lee NH; Piao HY; Fletcher CD; Kanki JP; Look AT
    Cancer Res; 2004 Oct; 64(20):7256-62. PubMed ID: 15492244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
    Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
    PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures.
    Schoof M; Godbole S; Albert TK; Dottermusch M; Walter C; Ballast A; Qin N; Olivera MB; Göbel C; Neyazi S; Holdhof D; Kresbach C; Peter LS; Epplen GD; Thaden V; Spohn M; Blattner-Johnson M; Modemann F; Mynarek M; Rutkowski S; Sill M; Varghese J; Afflerbach AK; Eckhardt A; Münter D; Verma A; Struve N; Jones DTW; Remke M; Neumann JE; Kerl K; Schüller U
    Nat Commun; 2023 Nov; 14(1):7717. PubMed ID: 38001143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
    Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
    Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors.
    Westerman BA; Blom M; Tanger E; van der Valk M; Song JY; van Santen M; Gadiot J; Cornelissen-Steijger P; Zevenhoven J; Prosser HM; Uren A; Aronica E; van Lohuizen M
    PLoS One; 2012; 7(5):e35943. PubMed ID: 22574128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary. A possible model for human multiple endocrine neoplasia type 1.
    Murphy D; Bishop A; Rindi G; Murphy MN; Stamp GW; Hanson J; Polak JM; Hogan B
    Am J Pathol; 1987 Dec; 129(3):552-66. PubMed ID: 2827490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.